These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 33367811)

  • 41. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials.
    Zoungas S; Arima H; Gerstein HC; Holman RR; Woodward M; Reaven P; Hayward RA; Craven T; Coleman RL; Chalmers J;
    Lancet Diabetes Endocrinol; 2017 Jun; 5(6):431-437. PubMed ID: 28365411
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prognostic impact of visit-to-visit glycemic variability on the risks of major adverse cardiovascular outcomes and hypoglycemia in patients with different glycemic control and type 2 diabetes.
    Sun B; He F; Gao Y; Zhou J; Sun L; Liu R; Xu H; Chen X; Zhou H; Liu Z; Zhang W
    Endocrine; 2019 Jun; 64(3):536-543. PubMed ID: 30868413
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Visit-to-Visit HbA
    Li S; Nemeth I; Donnelly L; Hapca S; Zhou K; Pearson ER
    Diabetes Care; 2020 Feb; 43(2):426-432. PubMed ID: 31727686
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The hemoglobin glycation index identifies subpopulations with harms or benefits from intensive treatment in the ACCORD trial.
    Hempe JM; Liu S; Myers L; McCarter RJ; Buse JB; Fonseca V
    Diabetes Care; 2015 Jun; 38(6):1067-74. PubMed ID: 25887355
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Association of long-term visit-to-visit variability of HbA1c and fasting glycemia with hypoglycemia in type 2 diabetes mellitus.
    Long C; Tang Y; Huang J; Liu S; Xing Z
    Front Endocrinol (Lausanne); 2022; 13():975468. PubMed ID: 36034445
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: the Verona Diabetes Study.
    Muggeo M; Zoppini G; Bonora E; Brun E; Bonadonna RC; Moghetti P; Verlato G
    Diabetes Care; 2000 Jan; 23(1):45-50. PubMed ID: 10857967
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Visit-to-visit variability of glycemia and vascular complications: the Hoorn Diabetes Care System cohort.
    Slieker RC; van der Heijden AAWH; Nijpels G; Elders PJM; 't Hart LM; Beulens JWJ
    Cardiovasc Diabetol; 2019 Dec; 18(1):170. PubMed ID: 31830993
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Fasting Plasma Glucose Variability and Gastric Cancer Risk in Individuals Without Diabetes Mellitus: A Nationwide Population-Based Cohort Study.
    Hong SH; Noh E; Kim J; Hwang SY; Kim JA; Lee YB; Roh E; Choi KM; Baik SH; Cho GJ; Yoo HJ
    Clin Transl Gastroenterol; 2020 Sep; 11(9):e00221. PubMed ID: 32858572
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Development and validation of optimal phenomapping methods to estimate long-term atherosclerotic cardiovascular disease risk in patients with type 2 diabetes.
    Segar MW; Patel KV; Vaduganathan M; Caughey MC; Jaeger BC; Basit M; Willett D; Butler J; Sengupta PP; Wang TJ; McGuire DK; Pandey A
    Diabetologia; 2021 Jul; 64(7):1583-1594. PubMed ID: 33715025
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The effects of fasting plasma glucose variability and time-dependent glycemic control on the long-term risk of retinopathy in type 2 diabetic patients.
    Takao T; Ide T; Yanagisawa H; Kikuchi M; Kawazu S; Matsuyama Y
    Diabetes Res Clin Pract; 2011 Feb; 91(2):e40-2. PubMed ID: 21035886
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Heterogeneous Treatment Effects of Intensive Glycemic Control on Kidney Microvascular Outcomes and Mortality in ACCORD.
    Charu V; Liang JW; Chertow GM; Li J; Montez-Rath ME; Geldsetzer P; de Boer IH; Tian L; Tamura MK
    J Am Soc Nephrol; 2024 Feb; 35(2):216-228. PubMed ID: 38073026
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of glycemic treatment choices on cardiovascular complications in type 2 diabetes.
    Weiss IA; Valiquette G; Schwarcz MD
    Cardiol Rev; 2009; 17(4):165-75. PubMed ID: 19525678
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Heterogeneous treatment effects of intensive glycemic control on major adverse cardiovascular events in the ACCORD and VADT trials: a machine-learning analysis.
    Edward JA; Josey K; Bahn G; Caplan L; Reusch JEB; Reaven P; Ghosh D; Raghavan S
    Cardiovasc Diabetol; 2022 Apr; 21(1):58. PubMed ID: 35477454
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Does aggressive glycemic control benefit macrovascular and microvascular disease in type 2 diabetes? Insights from ACCORD, ADVANCE, and VADT.
    Terry T; Raravikar K; Chokrungvaranon N; Reaven PD
    Curr Cardiol Rep; 2012 Feb; 14(1):79-88. PubMed ID: 22160862
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Issues surrounding tight glycemic control in people with type 2 diabetes mellitus.
    Cerveny JD; Leder RD; Weart CW
    Ann Pharmacother; 1998 Sep; 32(9):896-905. PubMed ID: 9762378
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Relationship between vitamin D status and incidence of vascular events in the Veterans Affairs Diabetes Trial.
    Alele JD; Luttrell LM; Hollis BW; Luttrell DK; Hunt KJ;
    Atherosclerosis; 2013 Jun; 228(2):502-7. PubMed ID: 23608249
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Optimal cutoff values of fasting plasma glucose (FPG) variability for detecting retinopathy and the threshold of FPG levels for predicting the risk of retinopathy in type 2 diabetes: A longitudinal study over 27 years.
    Takao T; Inoue K; Suka M; Yanagisawa H; Iwamoto Y
    Diabetes Res Clin Pract; 2018 Jun; 140():228-235. PubMed ID: 29625141
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Fasting plasma glucose variability and all-cause mortality among type 2 diabetes patients: a dynamic cohort study in Shanghai, China.
    Xu D; Fang H; Xu W; Yan Y; Liu Y; Yao B
    Sci Rep; 2016 Dec; 6():39633. PubMed ID: 28004765
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term glucose variability and incident cardiovascular diseases and all-cause mortality events in subjects with and without diabetes: Tehran Lipid and Glucose Study.
    Barzegar N; Ramezankhani A; Tohidi M; Azizi F; Hadaegh F
    Diabetes Res Clin Pract; 2021 Aug; 178():108942. PubMed ID: 34245796
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Visit-to-visit variation of fasting plasma glucose is a predictor of hip fracture in older persons with type 2 diabetes: the Taiwan Diabetes Study.
    Chiang JI; Li TC; Li CI; Liu CS; Meng NH; Lin WY; Yang SY; Chen HJ; Lin CC
    Osteoporos Int; 2016 Dec; 27(12):3587-3597. PubMed ID: 27363401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.